The CRF System as a Therapeutic Target for Neuropsychiatric Disorders

Trends in Pharmacological Sciences

Volumn 37, Issue 12, 2016, Pages 1045-1054

  Sanders, Jeff ^a   Nemeroff, Charles ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CRF; polymorphisms; preclinical; psychopathology; stress; treatment

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; ANTIDEPRESSANT AGENT; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CP 316311; G PROTEIN COUPLED RECEPTOR KINASE; MESSENGER RNA; PEXACERFONT; UNCLASSIFIED DRUG; VERUCERFONT; CORTICOTROPIN RELEASING FACTOR RECEPTOR;

ADDICTION; ALCOHOLISM; ANXIETY DISORDER; BINDING AFFINITY; BRAIN REGION; DEPRESSION; DISORDERS OF HIGHER CEREBRAL FUNCTION; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EATING DISORDER; FEEDING DISORDER; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; MOOD DISORDER; NERVE CELL; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANCE ABUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; MENTAL DISORDERS; METABOLISM; MOLECULARLY TARGETED THERAPY; NERVOUS SYSTEM DISEASES; PATHOPHYSIOLOGY;

ANIMALS; CORTICOTROPIN-RELEASING HORMONE; DRUG DESIGN; HUMANS; MENTAL DISORDERS; MOLECULAR TARGETED THERAPY; NERVOUS SYSTEM DISEASES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 84995799449     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.09.004     Document Type: Review

References (80)

1. 1 Ledford, H., Medical research: if depression were cancer. Nature 515 (2014), 182–184.
2. 2 Trivedi, M.H., et al. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J. Clin. Psychiatry 69 (2008), 246–258.
3. 1 receptor antagonists to treat alcoholism. Drug Alcohol Depend. 128 (2013), 175–186.
4. 4 Hauger, R.L. et al. (206) Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol. Disord. Drug Targets 5, 453–479.
5. 5 Nemeroff, C.B., et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226 (1984), 1342–1344.
6. 6 Bremner, J.D., et al. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am. J. Psychiatry 154 (1997), 624–629.
7. 7 Anthony, T.E., et al. Control of stress-induced persistent anxiety by an extra-amygdala septohypothalamic circuit. Cell 156 (2014), 522–536.
8. 8 Gray, J.M., et al. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J. Neurosci. 35 (2015), 3879–3892.
9. 9 Klampfl, S.M., et al. Hypoactivation of CRF receptors, predominantly type 2, in the medial-posterior BNST is vital for adequate maternal behavior in lactating rats. J. Neurosci. 34 (2014), 9665–9676.
10. 10 Lemos, J.C., et al. Severe stress switches CRF action in the nucleus accumbens from appetitive to aversive. Nature 490 (2012), 402–406.
11. 11 Bale, T.L., Vale, W.W., CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 44 (2004), 525–557.
12. 12 Sautter, F.J., et al. Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol. Psychiatry 54 (2003), 1382–1388.
13. 13 Bale, T.L., Chen, A., Minireview: CRF and Wylie Vale: a story of 41 amino acids and a Texan with grit. Endocrinology 153 (2012), 2556–2561.
14. 14 Zmijewski, M.A., Slominski, A.T., Emerging role of alternative splicing of CRF1 receptor in CRF signaling. Acta Biochim. Pol. 57 (2010), 1–13.
15. 15 Wu, S.V., et al. Activation of type 1 CRH receptor isoforms induces serotonin release from human carcinoid BON-1N cells: an enterochromaffin cell model. Endocrinology 152 (2011), 126–137.
16. 16 Teli, T., et al. Structural domains determining signalling characteristics of the CRH-receptor type 1 variant R1β and response to PKC phosphorylation. Cell. Signal. 20 (2008), 40–49.
17. 17 Grammatopoulos, D.K., Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction. Br. J. Pharmacol. 166 (2012), 85–97.
18. 18 Zmijewski, M.A., Slominski, A.T., Modulation of corticotropin releasing factor (CRF) signaling through receptor splicing in mouse pituitary cell line AtT-20 – emerging role of soluble isoforms. J. Physiol. Pharmacol. 60:Suppl. 4 (2009), 39–46.
19. 19 Waselus, M., et al. Stress-induced redistribution of corticotropin-releasing factor receptor subtypes in the dorsal raphe nucleus. Biol. Psychiatry 66 (2009), 76–83.
20. 20 Miguel, T.T., et al. Tonic modulation of anxiety-like behavior by corticotropin-releasing factor (CRF) type 1 receptor (CRF1) within the medial prefrontal cortex (mPFC) in male mice: role of protein kinase A (PKA). Horm. Behav. 66 (2014), 247–256.
21. 21 Toth, M., et al. The role of PKC signaling in CRF-induced modulation of startle. Psychopharmacology (Berl) 229 (2013), 579–589.
22. 22 Punn, A., et al. Identification of signaling molecules mediating corticotropin-releasing hormone-R1(-mitogen-activated protein kinase (MAPK) interactions: the critical role of phosphatidylinositol 3-kinase in regulating ERK1/2 but not p38 MAPK activation. Mol. Endocrinol. 20 (2006), 3179–3195.
23. 23 Narla, C., et al. A switch in G protein coupling for type 1 corticotropin-releasing factor receptors promotes excitability in epileptic brains. Sci. Signal., 9, 2016, ra60.
24. 24 Grieder, T.E., et al. VTA CRF neurons mediate the aversive effects of nicotine withdrawal and promote intake escalation. Nat. Neurosci. 17 (2014), 1751–1758.
25. 25 Elharrar, E., et al. Overexpression of corticotropin-releasing factor receptor type 2 in the bed nucleus of stria terminalis improves posttraumatic stress disorder-like symptoms in a model of incubation of fear. Biol. Psychiatry 74 (2013), 827–836.
26. 26 Zaidan, H., et al. Prereproductive stress to female rats alters corticotropin releasing factor type 1 expression in ova and behavior and brain corticotropin releasing factor type 1 expression in offspring. Biol. Psychiatry 74 (2013), 680–687.
27. 2(a) receptor signaling governed by agonist potency and βarrestin2 recruitment. Regul. Pept. 186 (2013), 62–76.
28. 28 Hammad, M.M., et al. Role of cystic fibrosis transmembrane conductance regulator-associated ligand (CAL) in regulating the trafficking and signaling of corticotropin-releasing factor receptor 1. Cell. Signal. 27 (2015), 2120–2130.
29. 29 Dunn, H.A., et al. PSD-95 regulates CRFR1 localization, trafficking and β-arrestin2 recruitment. Cell. Signal. 28 (2016), 531–540.
30. 30 Slater, P.G., et al. CRF binding protein facilitates the presence of CRF type 2α receptor on the cell surface. Proc. Natl. Acad. Sci. U.S.A. 113 (2016), 4075–4080.
31. 31 Dong, H., et al. Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-beta and behavior in Tg2576 mice. Psychopharmacology (Berl) 231 (2014), 4711–4722.
32. 32 Micioni Di Bonaventura, M.V., et al. Role of bed nucleus of the stria terminalis corticotrophin-releasing factor receptors in frustration stress-induced binge-like palatable food consumption in female rats with a history of food restriction. J. Neurosci. 34 (2014), 11316–11324.
33. 33 Diagnostic and Statistical Manual of Mental Disorders Fifth Edition. 2013, American Psychiatric Publishing.
34. 34 Schatzberg, A.F., et al. HPA axis genetic variation, cortisol and psychosis in major depression. Mol. Psychiatry 19 (2014), 220–227.
35. 35 Hsu, D.T., et al. Variation in the corticotropin-releasing hormone receptor 1 (CRHR1) gene influences fMRI signal responses during emotional stimulus processing. J. Neurosci. 32 (2012), 3253–3260.
36. 36 Raadsheer, F.C., et al. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am. J. Psychiatry 152 (1995), 1372–1376.
37. 37 Binder, E.B., Nemeroff, C.B., The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol. Psychiatry 15 (2010), 574–588.
38. 38 Merali, Z., et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABAA receptor subunits in frontal cortical brain region. J. Neurosci. 24 (2004), 1478–1485.
39. 39 Bradley, R.G., et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch. Gen. Psychiatry 65 (2008), 190–200.
40. 40 Polanczyk, G., et al. Protective effect of CRHR1 gene variants on the development of adult depression following childhood maltreatment: replication and extension. Arch. Gen. Psychiatry 66 (2009), 978–985.
41. 41 Ressler, K.J., et al. Polymorphisms in CRHR1 and the serotonin transporter loci: gene × gene × environment interactions on depressive symptoms. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B (2010), 812–824.
42. 42 Todorovic, C., et al. Suppression of the MEK/ERK signaling pathway reverses depression-like behaviors of CRF2-deficient mice. Neuropsychopharmacology 34 (2010), 1416–1426.
43. 43 Kolber, B.J., et al. Transient early-life forebrain corticotropin-releasing hormone elevation causes long-lasting anxiogenic and despair-like changes in mice. J. Neurosci. 30 (2010), 2571–2581.
44. 44 Regev, L., et al. Prolonged and site-specific over-expression of corticotropin-releasing factor reveals differential roles for extended amygdala nuclei in emotional regulation. Mol. Psychiatry 16 (2011), 714–728.
45. 45 Bourke, C.H., et al. SSRI or CRF antagonism partially ameliorate depressive-like behavior after adolescent social defeat. Behav. Brain Res. 270 (2014), 295–299.
46. 46 Held, K., et al. Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J. Psychiatr. Res. 38 (2004), 129–136.
47. 47 Zobel, A.W., et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34 (2000), 171–181.
48. 48 Paez-Pereda, M., et al. Corticotropin releasing factor receptor antagonists for major depressive disorder. Expert Opin. Investig. Drugs 20 (2011), 519–535.
49. 49 Binneman, B., et al. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry 165 (2008), 617–620.
50. 50 White, S., et al. Association of CRHR1 variants and posttraumatic stress symptoms in hurricane exposed adults. J. Anxiety Disord. 27 (2013), 678–683.
51. 51 Wolf, E.J., et al. Corticotropin releasing hormone receptor 2 (CRHR-2) gene is associated with decreased risk and severity of posttraumatic stress disorder in women. Depress. Anxiety 30 (2013), 1161–1169.
52. 52 Amstadter, A.B., et al. Corticotrophin-releasing hormone type 1 receptor gene (CRHR1) variants predict posttraumatic stress disorder onset and course in pediatric injury patients. Dis. Markers 30 (2011), 89–99.
53. 53 Rajbhandari, A.K., et al. Predator Stress-Induced CRF Release Causes Enduring Sensitization of Basolateral Amygdala Norepinephrine Systems that Promote PTSD-Like Startle Abnormalities. J. Neurosci. 35 (2015), 14270–14285.
54. 54 Philbert, J., et al. The CRF1 receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: comparison with paroxetine and D-cycloserine. Behav. Brain Res. 279 (2015), 41–46.
55. 55 Dunlop, B.W., et al. Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials, 15, 2014, 240.
56. 56 Ribbe, K., et al. Prediction of the risk of comorbid alcoholism in schizophrenia by interaction of common genetic variants in the corticotropin-releasing factor system. Arch. Gen. Psychiatry 68 (2011), 1247–1256.
57. 57 Ray, L.A., et al. The CRHR1 gene, trauma exposure, and alcoholism risk: a test of G × E effects. Genes Brain Behav. 12 (2013), 361–369.
58. 58 Schmid, B., et al. Interacting effects of CRHR1 gene and stressful life events on drinking initiation and progression among 19-year-olds. Int. J. Neuropsychopharmacol. 13 (2010), 703–714.
59. 59 Glaser, Y.G., et al. Indirect effect of corticotropin-releasing hormone receptor 1 gene variation on negative emotionality and alcohol use via right ventrolateral prefrontal cortex. J. Neurosci. 34 (2014), 4099–4107.
60. 60 Chen, N.A., et al. Knockdown of CRF1 receptors in the ventral tegmental area attenuates cue- and acute food deprivation stress-induced cocaine seeking in mice. J. Neurosci. 34 (2014), 11560–11570.
61. 61 Holly, E.N., et al. Episodic Social Stress-Escalated Cocaine Self-Administration: Role of Phasic and Tonic Corticotropin Releasing Factor in the Anterior and Posterior Ventral Tegmental Area. J. Neurosci. 36 (2016), 4093–4105.
62. 62 Boyson, C.O., et al. Social stress and CRF-dopamine interactions in the VTA: role in long-term escalation of cocaine self-administration. J. Neurosci. 34 (2014), 6659–6667.
63. 63 Rinker, J.A., et al. Extended amygdala to ventral tegmental area corticotropin-releasing factor circuit controls binge ethanol intake. Biol. Psychiatry, 2016.
64. 64 Vranjkovic, O., et al. Stress-induced cocaine seeking requires a (-2 adrenergic receptor-regulated pathway from the ventral bed nucleus of the stria terminalis that regulates CRF actions in the ventral tegmental area. J. Neurosci. 34 (2014), 12504–12514.
65. 65 Koob, G.F., The dark side of emotion: the addiction perspective. Eur. J. Pharmacol. 753 (2015), 73–87.
66. 66 Zhao-Shea, R., et al. Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal. Nat. Commun., 6, 2015, 6770.
67. 67 Qi, X., et al. Sustained AAV-mediated overexpression of CRF in the central amygdala diminishes the depressive-like state associated with nicotine withdrawal. Transl. Psychiatry, 4, 2014, e385.
68. 68 Kwako, L.E., et al. The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. Neuropsychopharmacology 40 (2015), 1053–1063.
69. 69 Schwandt, M.L., et al. The CRF1 antagonist verucerfont in anxious alcohol dependent women: translation of neuroendocrine, but not of anti-craving effects. Neuropsychopharmacology, 2016.
70. 70 Fossey, M.D., et al. Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol. Psychiatry 39 (1996), 703–707.
71. 71 Keck, M.E., et al. Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B (2008), 1196–1204.
72. 72 Demers, C.H., et al. Interactions between anandamide and corticotropin-releasing hormone signaling modulate human amygdala function and risk for anxiety disorders: an imaging genetics strategy for modeling molecular interactions. Biol. Psychiatry 80 (2016), 356–362.
73. 73 Coric, V., et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress. Anxiety 27 (2010), 417–425.
74. 74 Hotta, M., et al. The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients. J. Clin. Endocrinol. Metab. 62 (1986), 319–324.
75. 75 Veitch, D.P., et al. Military risk factors for cognitive decline, dementia and Alzheimer's disease. Curr. Alzheimer Res. 10 (2013), 907–930.
76. 76 Justice, N.J., et al. Posttraumatic stress disorder-like induction elevates beta-amyloid levels, which directly activates corticotropin-releasing factor neurons to exacerbate stress responses. J. Neurosci. 35 (2015), 2612–2623.
77. 77 Nemeroff, C.B., et al. Neuropeptides in Alzheimer's disease: a postmortem study. Regul. Pept. 25 (1989), 123–130.
78. 78 Rissman, R.A., et al. Corticotropin-releasing factor receptor-dependent effects of repeated stress on tau phosphorylation, solubility, and aggregation. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), 6277–6282.
79. 79 Carr, C.P., et al. The role of early life stress in adult psychiatric disorders: a systematic review according to childhood trauma subtypes. J. Nerv. Ment. Dis. 201 (2013), 1007–1020.
80. 80 Lodge, N.J., et al. Synthesis and evaluation of candidate PET radioligands for corticotropin-releasing factor type-1 receptors. Nucl. Med. Biol. 41 (2014), 524–535.